Oncotarget

Research Papers:

Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma

Chinthalapally V. Rao _, Naveena B. Janakiram, Venkateshwar Madka, Vishal Devarkonda, Misty Brewer, Laura Biddick, Stan Lightfoot, Vernon E. Steele and Altaf Mohammed

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:33290-33305. https://doi.org/10.18632/oncotarget.5396

Metrics: PDF 1183 views  |   HTML 1852 views  |   ?  


Abstract

Chinthalapally V. Rao1, Naveena B. Janakiram1, Venkateshwar Madka1, Vishal Devarkonda1, Misty Brewer1, Laura Biddick1, Stan Lightfoot1, Vernon E. Steele2, Altaf Mohammed1

1Center for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

2Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, Bethesda, MD, USA

Correspondence to:

Chinthalapally V. Rao, e-mail: cv-rao@ouhsc.edu

Altaf Mohammed, e-mail: altaf-mohammed@ouhsc.edu

Keywords: chemoprevention, inflammation, EGFR, pancreatic cancer

Received: July 31, 2015     Accepted: September 16, 2015     Published: September 28, 2015

ABSTRACT

Cyclooxygenase-2 (COX-2), 5-Lipoxygenase (5-LOX), and epidermal growth factor receptor (EGRF) are over-expressed in human pancreatic ductal adenocarcinoma (PDAC). Using next-generation sequencing (NGS) analysis, we show significant increase in COX-2, 5-LOX, and EGFR expression during PDAC progression. Targeting complementary pathways will achieve better treatment efficacy than a single agent high-dose strategy that could increase risk of side effects and tumor resistance. To target COX-2, 5-LOX, and EGFR simultaneously, we tested effects of licofelone (dual 5-LOX-COX inhibitor), and gefitinib (EGFR inhibitor), individually and in combination, on pancreatic intraepithelial neoplasms (PanINs) and their progression to PDAC using genetically engineered mice. Individually, licofelone (L) and gefitinib (G) significantly inhibited incidence of PDAC in male (72% L, 90% G, p < 0.0001) and female (90% L, 85% G, p < 0.0001) mice. The combination drug treatment produced complete inhibition of PDAC in both genders. Pancreata of mice receiving combination treatment showed significantly fewer Dclk1-positive cancer stem-like cells, inhibition of COX-2, 5-LOX, PCNA, EGFR and β-catenin expression (p < 0.05–0.0002), increased p21 expression. Significant changes in tumor immune responses and desmoplastic reaction was observed by NGS analysis in combination treatment (p < 0.05). In summary, early simultaneous targeting of 5-LOX-COX- and EGFR pathways may provide additive inhibitory effects leading to complete suppression of PDAC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5396